Sun, Jan 25, 2015, 4:23 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • batzem batzem Jan 10, 2012 7:35 PM Flag


    Celegen announced preliminary 2011 sales of just over 700 million dollars up 32%.

    Nice to dream what this stock could be if S110 ever gets to the finish line or even publishes some positive phase 2 data.

    For now would be thrilled with EU approval of elderly aml indication for dacogen

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • In yesterday's presentation, Manuso said the hypomethylating market is a 900 million dollar market, so if Vidaza gets 700 million of it, Dacogen is only getting 200 million.

      If Dacogen can get approval for AML here and in the EU, those numbers can change big time.

      And like you say, if SGI 110 can fly, it will be Katy bar the door. I could easily see SGI110 gaining over 1.5 billion in sales, especially if it can be used against solid tumors.

      • 2 Replies to jelly1126
      • I have heard M@!#!@# say the same thing Jelly but always thought he said the market share was 60/40 Vidaza. Numbers don't add up then with the $700M/$200M split. Wonder are we talking US sales only or are the Vidaza worldwide sales. Thought the $900M number that M@$##! talks about was WW sales. He has talked about this number for 6 months now.

        Any ideas on what we are talking about in sales if Dacogen is approved for AML here and the EU? Recall M!@#!@ saying it was a larger revenue base than they currently have.


      • When you look at Inhibitex with a phase 2 drug that 3 months ago was under 3 dollars and today is 24 dollars you can appreciate the explosivenss that S110 could create.

        The comparable size of Supg and Inhx was interesting in terms of float, cash , market cap the main difference is we;re not lucky yet

8.4950.0000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.